Regeneron

Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
Regeneron, Sanofi talks up potential blockbuster franchise as Dupixent sweeps in rhinosinusitis PhIII
Endpoints
Regeneron
Sanofi
Dupixent
nasal polyps
rhinosinusitis
Flag link:
7 drugmakers to watch during Q3 earnings
7 drugmakers to watch during Q3 earnings
Biopharma Dive
earnings
Novartis
Gilead Sciences
Amgen
Pfizer
GSK
AbbVie
Regeneron
Flag link:
In Medical Reporting, the Impact of Patients’ Stories
In Medical Reporting, the Impact of Patients’ Stories
NY Times, NY
patients
journalists
Regeneron
Flag link:
Regeneron, Sanofi Win Approval for Their First Immuno-Oncology Drug
Regeneron, Sanofi Win Approval for Their First Immuno-Oncology Drug
Bloomberg
Regeneron
Sanofi
Libtayo
immuno-oncology
skin cancer
FDA
Flag link:
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
3 Drugmakers Not Pleased With Amarin's Fish Oil Triumph
Yahoo/Motley Fool
Amarin
Vascepa
Amgen
Sanofi
Regeneron
Flag link:
FDA to review Regeneron’s Eylea for diabetic retinopathy
FDA to review Regeneron’s Eylea for diabetic retinopathy
Drug Delivery Business News
Regeneron
FDA
Eylea
diabetic retinopathy
Flag link:
Regeneron will invest $800 million, expand workforce by 1,500
Regeneron will invest $800 million, expand workforce by 1,500
Bizjournals.com
Regeneron
drug manufacturing
New York
Flag link:
Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack
Just a few days after a stumble, FDA OKs 12-week dose for Eylea as Regeneron braces for Novartis attack
Endpoints
FDA
Eylea
Regeneron
Novartis
wet age-related macular degeneration
Flag link:
Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
CP Wire
Teva Pharmaceutical
Regeneron
fasinumab
osteoarthritis
Flag link:
Teva and Regeneron's Fasinumab Meets Primary and Secondary Endpoints in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Teva Pharmaceutical
Regeneron
fasinumab
osteoarthritis
Flag link:
Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
Racing Novartis on Eylea rival, the FDA trips up Regeneron at the finish line
Endpoints
Regeneron
Eylea
Novartis
RTH258
wet age-related macular degeneration
FDA
Flag link:
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Regeneron And Bluebird Team To Invent New Cell Therapies For Cancer
Forbes
Regeneron
Bluebird Bio
CAR-T
drug discovery
gene therapy
cancer
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
biotech
IPOs
Pain Therapeutics
Remoxy
Vertex Pharmaceuticals
lumacaftor/ivacaftor
Alnylam
Patisiran
Regeneron
Eylea
Insmed
Paratek
Vaccinex
Flag link:
Regeneron plots DTC advertising and discount push to put Eylea back on track
Regeneron plots DTC advertising and discount push to put Eylea back on track
Fierce Pharma
Regeneron
Sanofi
Eylea
DTC advertising
Flag link:
Regeneron’s Billionaire Founder Battles The Drug Pricing System
Regeneron’s Billionaire Founder Battles The Drug Pricing System
Forbes
Regeneron
Leonard Schleifer
drug pricing
Flag link:
Allergan’s eye contender cannot knock Eylea off its perch
Allergan’s eye contender cannot knock Eylea off its perch
EP Vantage
Regeneron
Eylea
wet age-related macular degeneration
Allergan
molecular
abicipar
Flag link:
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
Regeneron, Sanofi show restraint on Dupixent price hike, but Pfizer’s hard charge continues to spur calls for a radical change-up
Endpoints
Regeneron
Sanofi
Dupixent
drug pricing
Flag link:
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
Regeneron Focuses on Expanding Eylea’s Diabetic Retinopathy Label
Market Realist
Regeneron
FDA
Eylea
diabetic retinopathy
Flag link:
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
Endpoints
M&A
JNJ
Merck
Pfizer
Gilead Sciences
Amgen
Biogen
Takeda
Regeneron
Alexion
Flag link:

Pages